Investigating how inflammation affects cognitive decline in aging and Alzheimer's disease
Metabolic mechanisms of cognitive decline in aging and AD mediated by inflammatory PGE2 signaling
This study is looking at how a molecule called prostaglandin E2 (PGE2) affects brain health as we age and in people with Alzheimer's, and it aims to find ways to help improve thinking and memory by targeting this molecule in immune cells, which could lead to new treatments for older adults.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-10590390 on NIH RePORTER |
What this research studies
This research explores the role of inflammatory signaling, specifically through a molecule called prostaglandin E2 (PGE2), in cognitive decline associated with aging and Alzheimer's disease (AD). The study aims to understand how inhibiting this inflammatory pathway can restore healthy brain function by focusing on immune cells in the body. By examining the effects of PGE2 on these immune cells, researchers hope to identify new therapeutic strategies that could improve cognitive health in older adults. The approach includes both genetic and pharmacological methods to assess the impact of PGE2 signaling on brain health.
Who could benefit from this research
Good fit: Ideal candidates for this research include older adults experiencing cognitive decline or those diagnosed with Alzheimer's disease.
Not a fit: Patients with cognitive decline due to non-inflammatory causes or those who are not within the aging population may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that slow down or prevent cognitive decline in aging and Alzheimer's patients.
How similar studies have performed: Previous research has shown promising results in targeting inflammatory pathways to improve cognitive function, indicating that this approach may be effective.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Andreasson, Katrin I. — Stanford University
- Study coordinator: Andreasson, Katrin I.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.